Register for our free email digests:
Latest From NeoTract Inc.
Teleflex is forking out over $1bn for privately held NeoTract. The latter has seen its revenues grow rapidly due to market enthusiasm for its UroLift system for treating lower urinary tract symptoms related to benign prostatic hyperplasia.
New Enterprise Associates surprised some by locking down $3.1 billion in new capital during a tight fundraising climate. General partner David Mott and partner Justin Klein share the firm’s investment approach.
NICE Guidance: Prostatic Implants, RF Ablation For Snoring, Transcranial Stimulation For Migraine, Arthroscopic Kneecap Surgery
The influential U.K. institute approves the use of prostatic urethral lift implants to treat urinary symptoms in men with benign prostatic hyperplasia, as well as radiofrequency ablation of the soft palate to treat snoring. Transcranial magnetic stimulation for migraine and arthroscopic trochleoplasty to treat patellar instability don’t fare as well.
Regulatory Briefs: Comment Period For Masked Data Release Reopened; Studies On 510(k), Post-Market Programs
FDA has reopened the comment period for its proposal to release masked trial data. The HHS Office of Inspector General released a study on FDA classification of class III pre-amendment devices. More regulatory news.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Gynecological, Urological
- North America
- Parent & Subsidiaries
- NeoTract Inc.
- Senior Management
David Amerson, Pres. & CEO
Doug Hughes, CFO
Joseph Catanese, III, PhD, VP, R&D
Richard Walsh, VP, International Sales
- Contact Info
Phone: (925) 401-0700
4473 Willow Rd.
Pleasonton, CA 94588
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.